Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue

International Urology and Nephrology

Volumn 39, Issue 3, 2007, Pages 841-850

  Kaygusuz, Gulsah ^a   Tulunay, Ozden ^a   Baltaci, Sumer ^a   Gogus, Orhan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Angiogenesis factors; Immunohistochemistry; MVD; Prostate; Prostate cancer

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CD34 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; THROMBOSPONDIN 1; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RISK FACTOR; TUMOR VASCULARIZATION;

AGED; CORNEAL STROMA; CYTOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; THROMBOSPONDIN 1; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548446819     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-006-9144-z     Document Type: Article

References (48)

1. Folkman J, Watson K, Ingber D, et al. (1989) Introduction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61
2. Weidner N, Carroll PR, Flax J, et al. (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409
3. Tuxhorn JA, Ayala GE, Rowley DR (2001) Reactive stroma in prostate cancer progression. J Urol 166:2472-2483
4. Doll JA, Reiher FK, Crawford SE, et al. (2001) Trombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49:293-305
5. Baltaci S, Orhan D, Gogus C, et al. (2003) Thrombospondin-1, vascular endothelial growth factor expression and microvessel density in renal cell carcinoma and their relationship with multifocality. Eur Urol 44: 76-81, discussion 81
6. Yaman O, Ozdiler E, Orhan D, et al. (1997) Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms. Urol Int 58: 199-202
7. Shih SC, Robinson GS, Perruzzi CA, et al. (2002) Molecular profiling of angiogenesis markers. Am J Pathol 161:35-41
8. Good DJ, Polverini PJ, Rastinejad F, et al. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Science 87:6624-6628
9. Iruela-Arispe ML, Bornstein P, Sage H (1991) Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 88:5026-5030
10. Tolsma SS, Volpert OV, Good DJ, et al. (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511
11. Pedersen KV, Herder A (1993) Radical retropubic prostatectomy for localised prostatic carcinoma: A clinical and pathological study of 201 cases. Scand J Urol Nephrol 27:219-224
12. Moreno JG, Ahlering TE (1992) Late local complications after definitive radiotherapy for prostatic adenocarcinoma. J Urol 147(3pt 2):926-928
13. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64
14. Oesterling JE (1991) Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923
15. Condon MS (2005) The role of the stromal microenvironment in prostate cancer. Sem Cancer Biol 15:132-137
16. Tuxhorn JA, McAlhany SJ, Dang TD, et al. (2002) Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62:3298-3307
17. Cockerill GW, Gamble JR, Vadas MA (1995) Angiogenesis: Models and modulators. Int Rev Cytol 159:113-160
18. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. (1998) CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160:459-465
19. Bono AV, Celato N, Cova V, et al. (2002) Microvessel density in prostate carcinoma. Prostate Cancer 5:123-127
20. Houck KA, Leung DW, Rowland AM, et al. (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037
21. Rak J, Filmus J, Finkenzeller G, et al. (1995) Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14:263-277
22. Walsh K, Sriprasad S, Hopster D, et al. (2002) Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Prostate Cancer 5:119-122
23. Mori H, Maki M, Oishi K, et al. (1990) Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 16:71-80
24. Deshmukh N, Scotson J, Dodson AR, et al. (1997) Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry. Br J Urol 80:869-874
25. Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063-1071
26. Walsh, Sherwood RA, Dew TK, et al. (1999) Angiogenesis peptides in prostattic disease. Br J Urol Int 8:1081-1083
27. Trojan L, Thomas D, Knoll T, et al. (2004) Expression of VEGF, EGF and bFGF and their topographical relation to neovascularization in prostate cancer. Urol Res 32:97-103
28. Brown LF, Guidi AJ, Schnitt SJ, et al. (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041-1056
29. Nicosia RF, Tuszynski GP (1994) Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 124:183-193
30. Bleuel K, Popp S, Fusenig NE, et al. (1999) Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vasculature. Proc Natl Acad Sci USA 96:2065-2070
31. Streit M, Velasco P, Brown LF, et al. (1999) Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155:441-452
32. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential and angiogenesis. Cancer Res 54:6504-6511
33. Chen H, Herndon ME, Lawler J (2000) The cell biology of thrombospondin. Matrix Biol 19:597-614
34. Good DJ, Polverini PJ, Rastinejad F, et al. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistiguishable from a fragment of thrombospondin. Proc. Natl Acad Sci USA 87:6624-6628
35. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. (2001) Thrombospondin-1 supresses tumor growth by a novel mechanism that includes blockade of matrix metalloproteinase-9 activation. Proc Natl Acad Sci USA 98:12485-12490
36. Taraboletti G, Morbidelli L, Donnini S, et al. (2000) The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J 14:1674-1676
37. Trojan L, Thomas D, Knoll T, et al. (2004) Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularization in prostate cancer. Urol Res 32:97-103
38. Wight TN, Raugi GJ, Mumby SM, et al. (1985) Light miscroscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 33:295-302
39. Kallakury BV, Figge J, Ross JS, et al. (1994) Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 25:92-97
40. Moul JW (1999) Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 35:399-407
41. Dameron KM, Volpert OV, Tainsky MA, et al. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584
42. Volpert OV, Dameron KM, Bouck N (1997) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14:1495-1502
43. Kwak C, Jin RJ, Lee C, et al. (2002) Trombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. Br J Urol 8:303-309
44. Mukhopadhyay D, Tsiokas L, Sukhatme VP (1995) Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55:6161-6165
45. Grossfeld GD, Ginsberg DA, Stein JP, et al. (1997) Thrombospondin-1 expression in bladder cancer: A association with p53 alterations, tumor angiogenesis and tumor progression. J Natl Cancer Inst 89:219-227
46. Royuela M, de Miguel MP, Ruiz A, et al. (2000) Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: Parallelism with c-myc and p53 expression. Eur Cytokine Netw 11:119-127
47. Lin DW, Noreboom JL, Blumenstein BA, et al. (1998) Serum percent free prostate-specific antigen in metastatic prostate cancer. Urology 52:366-371
48. Yu KK, Hawkins RA (2000) The prostate: Diagnostic evaluation of metastatic disease. Radiol Clin North Am 38:139-157